






Balloon-expandable transaortic transcatheter aortic valve
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Objective: It has been reported that balloon aortic valvuloplasty immediately
before transfemoral or transapical transcatheter aortic valve implantation has
mostly little to no clinical value. We aimed to provide data on the need for balloon
aortic valvuloplasty in patients undergoing transaortic transcatheter aortic valve
implantation.
Methods: Patients undergoing transaortic transcatheter aortic valve implanta-
tion with the Edwards SAPIEN XT (Nyon, Switzerland) or 3 transcatheter
heart valve were prospectively included at 18 sites across Europe. In the pre-
sent analysis, we compare the periprocedural and 30-day outcomes of
patients undergoing conventional (þ balloon aortic valvuloplasty) versus
direct ( balloon aortic valvuloplasty) transaortic transcatheter aortic valve
implantation.
Results: Of the 300 patients enrolled, 222 underwent conventional and 78 under-
went direct transaortic transcatheter aortic valve implantation. Peak and mean
transvalvular gradients were improved in both groups with no significant differ-
ence between groups. Procedural duration, contrast agent volume, and require-
ment for postdilation were also comparable. A trend toward fewer
periprocedural complications was evident in the direct group (3.9% vs 11.3%;
P ¼ .053), with significantly lower rates of permanent pacemaker implantation
(0% vs 5.0%; P¼ .034). Balloon aortic valvuloplasty omission had no significant
effect on any of the 30-day safety and efficacy outcomes, including Valve Aca-
demic Research Consortium-2 composite end points (early safety events:
22.7% vs 17.4%, odds ratio, 1.17, 95% confidence interval, 0.53-2.62; clinical
efficacy events: 20.5% vs 18.7%, odds ratio, 1.14, 95% confidence interval,
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Predilation in transaortic TAVI procedures using an Ed-
wards SAPIEN (Nyon, Switzerland) balloon-
expandable valve seems to have little clinical value for
many patients and may result in a higher rate of PPI.Perspective
Although BAV predilation in TA- and TF-TAVI
seems to be of little clinical value, evidence for
this in TAo-TAVI is lacking. Our real-world
data reveal that many findings from TA and
TF studies also apply to TAo-TAVI and suggest
that omission of predilation may reduce peri-
procedural PPI. This is valuable knowledge
for informing surgical decisions and adds to
the limited data on TAo-TAVI.See Editorial Commentary page 924.From the aDepartment of Cardiac Surgery, Medical University Innsbruck, Innsbruck,
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Abbreviations and Acronyms
AV ¼ atrioventricular
BAV ¼ balloon aortic valvuloplasty
CI ¼ confidence interval
NYHA ¼ New York Heart Association
OR ¼ odds ratio
PAD ¼ peripheral artery disease
PPI ¼ permanent pacemaker implantation
PVL ¼ paravalvular leak
ROUTE ¼ Registry Of the Utilization of the TAo-
TAVI approach using the Edwards
SAPIEN Valve
STS ¼ Society of Thoracic Surgeons
TA ¼ transapical
TAo ¼ transaortic
TAVI ¼ transcatheter aortic valve implantation
TF ¼ transfemoral
THV ¼ transcatheter heart valve
VARC-2¼ Valve Academic Research Consortium-2
Scanning this QR codewill take
you to a supplemental video for
the article.
Conclusions: For many patients, balloon aortic valvulo-
plasty predilation seems to have little clinical value in trans-
aortic transcatheter aortic valve implantation using a
balloon expandable transcatheter valve and may result in
a higher rate of periprocedural complications, particularly
in terms of permanent pacemaker implantation. (J Thorac
Cardiovasc Surg 2018;155:915-23)




Balloon aortic valvuloplasty (BAV) predilation has gener-
ally been considered fundamental to the transcatheter aortic
valve implantation (TAVI) procedure to allow prior assess-
ment of the appropriate transcatheter heart valve (THV)
size, facilitate the crossing of the aortic annulus, and maxi-
mize the expansion of the prosthesis to minimize paravalv-
ular leak (PVL).1 However, predilation may contribute to
stroke and embolic event rates because of a marked
dislodgement of calcific debris.2 Furthermore, existing
studies on transfemoral (TF) and transapical (TA) TAVI
have all reported that omitting the predilation step (known
as ‘‘direct TAVI’’) results in a level of efficacy similar to
that of the conventional approach (þBAV predilation),916 The Journal of Thoracic and Cardiovascular Surgwith potential additional safety advantages.3-5 The latter
include lower rates of permanent pacemaker implantation
(PPI) and 30-day mortality,6 shorter procedural and fluoros-
copy times,3 and reduced contrast agent volumes.3,7 In
addition, several studies suggest a lower degree of PVL
after direct versus conventional TAVI,3,8 potentially
discrediting the aforementioned belief that BAV
predilation is imperative for successful THV landing and
apposition. Despite the accumulating data for TF- and
TA-TAVI, no studies comparing direct with conventional
TAo-TAVI have been published. Patients undergoing
TAo-TAVI are of particular interest, not only as a distinct
population but also because of key procedural characteris-
tics. Although TAVI via the short, antegrade TA access
route can be easily performed without BAV, its omission
during retrograde TF-TAVI is complicated by the long dis-
tance between the femoral access point and the aortic valve,
and by the unequal distribution of forces applied by the sur-
geon at the groin to different points of the catheter. This is a
particularly relevant problem in patients with a horizontal
annulus, severe kinking of the iliac vessels, or very sharp
angulation of the aortic arch. TAo-TAVI is the only
approach that combines retrograde insertion with direct
transmission of forces to the stenotic aortic valve because
of the proximity and angulation of the catheter entry site.
As such, TAo-TAVI theoretically can be used in the major-
ity of patients. The value of BAV predilation under these
particular circumstances merits evaluation.
The present analysis of the Registry Of the Utilization of
the TAo-TAVI approach using the Edwards SAPIEN Valve
(ROUTE) (Nyon, Switzerland) specifically focuses on the
clinical value of BAV predilation in TAo-TAVI. Our aim
was to evaluate the impact of the direct approach on proce-
dural aspects and short-term event rates in patients with se-
vere AS undergoing this procedure with the Edwards
SAPIEN XT or 3 THV.MATERIALS AND METHODS
Design
Data from the multicenter, multinational, prospective ROUTE registry
(NCT01991431) were used in the present analysis, the design and rationale
of which have been described.9,10 This registry was established in February
2013, with the aim of determining the overall safety and efficacy of the
TAo-TAVI approach. It received prior institutional review board approval
from the relevant ethics committees at each site. All patients included in
the registry provided written informed consent.
Study Participants
Patients were consecutively enrolled at 18 sites across Europe. Criteria
for inclusion were (1) age 18 years or more; (2) severe AS (defined as aortic
valve surface area<1.0 cm2 plus a mean transvalvular gradient>40 mm
Hg); (3) scheduled to undergo TAo-TAVI using the Edwards SAPIEN
XT or 3 THV; and (4) complying with the indications for this procedure
detailed in the ‘‘Instructions for Use.’’ Patients scheduled to undergo a
concomitant procedure were excluded. For more details on inclusion and
exclusion criteria, readers are referred to the registry design article.9ery c March 2018
FIGURE 1. Patient flow for present analysis. ROUTE, Registry Of the
Utilization of the TAo-TAVI approach using the Edwards SAPIEN Valve;
TAo-TAVI, transaortic transcatheter aortic valve implantation; BAV, balloon
aortic valvuloplasty; FU, follow-up.








In the present analysis, all patients who underwent the procedure with
the BAV predilation step (Video 1) includedwere classified as the ‘‘conven-
tional TAo-TAVI’’ group, whereas all those who underwent the procedure
with the BAV predilation step omitted were classified as the ‘‘direct TAo-
TAVI’’ group. The decision as towhether or not to performBAV predilation
was made at the discretion of the treating physician, independent of inclu-
sion in the registry.
Objectives
The primary objective of the present analysis was to compare the pro-
portion of patients in the direct versus conventional TAo-TAVI group
meeting Valve Academic Research Consortium-2 (VARC-2) early safety
and efficacy composite end points at 30 days.11 Early safety was defined
as a composite of all-cause mortality, nonfatal stroke/transient ischemic
attack, life-threatening bleeding, acute kidney injury stage 2 or 3, major
vascular complication, and valve-related dysfunction. Early efficacy was
defined as a composite of all-cause mortality, stroke, hospitalization for
valve-related symptoms, New York Heart Association (NYHA) class III
or IV, and valve-related dysfunction. The secondary objectives were to
establish the effect of BAV predilation on individual 30-day complica-
tion/event rates, as well as on periprocedural outcomes such as complica-
tion rates, procedural time, need for balloon postdilation, and contrast
agent use.
Statistical Analysis
All of the collected data were entered into a database by a physician or
study nurse via electronic case report forms; more than 20% of patients
were subjected to source data verification after registry completion.
All relevant data are expressed using descriptive statistics. Categoric
variables are presented as absolute numbers and percentages, and contin-
uous variables are given as means  standard deviation or median (inter-
quartile range). For comparisons between the conventional and direct
group, a chi-square test or Fisher exact test was used for categoric variables,
a t test for normally distributed continuous variables, and a Mann–Whitney
U test for non-normally distributed continuous variables. P values are of
descriptive nature only and are adjusted for multiplicity. A logisticVIDEO 1. Video showing the TAo-TAVI surgical procedure. Video avail-
able at: http://www.jtcvsonline.org/article/S0022-5223(17)32400-5/fulltext.
The Journal of Thoracic and Caregression adjusting for baseline characteristics (age, peripheral artery dis-
ease [PAD], moderate/severe regurgitation insufficiency, and NYHA class
III or IV and prior BAV) was used to evaluate the effect of omitting BAV
predilation on 30-day safety and efficacy outcomes. These data are pre-
sented as odds ratios (ORs) with 97.5% confidence intervals (CIs). A mul-
tiplicity adjusted alpha level of 0.025 was used. All data analysis was
carried out using Statistical Analysis System version 9.3 (SAS Institute
Inc, Cary, NC).RESULTS
A total of 301 patients who underwent TAo-TAVI were
enrolled in the ROUTE registry (Figure 1). Of these, 300 pa-
tients were eligible for the present analysis. Accordingly,
study participants were grouped into 222 patients (74%)
who underwent conventional TAo-TAVI (þBAV predila-
tion) and 78 patients (26%) who underwent direct TAo-
TAVI (BAV predilation).Baseline Patient Details
Overall, patients had a mean age of 81.7 years and a body
mass index of 26.4 kg/m2, and 53.7% were female, with no
significant differences between the conventional and direct
groups (Table 1). The proportions of patients with prior car-
diovascular interventions were also statistically comparable
(35.7% overall); however, a significantly higher proportion
of the direct group had received prior BAV (9.0% vs 2.7%
of the conventional group; P ¼ .019). Surgical risk deter-
mined by the Society of Thoracic Surgeons (STS) algorithm
was comparable between groups (9% overall). Of the co-
morbidities documented, only PAD was found to differ
significantly between groups, affecting 47.8% of conven-
tional compared with 26.9% of direct TAo-TAVI patients
(P ¼ .001).
A greater proportion of the conventional group was clas-
sified as NYHA class III/IV (81.4% vs 60.3% of the direct
group; P ¼ .001). The proportion of patients in the direct
TAo-TAVI group with moderate or severe regurgitation
insufficiency (23.1%) was more than double that of the con-
ventional TAo-TAVI group (10.8%; P ¼ .007).rdiovascular Surgery c Volume 155, Number 3 917
TABLE 1. Baseline patient and disease characteristics
Total (N ¼ 300)
mean ± SD/n/N (%)
Conventional
TAo-TAVI (N ¼ 222)
mean ± SD/n/N (%)
Direct TAo-TAVI
(N ¼ 78)




Age [y] 81.7  5.9 82.1  5.8 80.7  6.3 .069
Female gender 161/300 (53.7) 121/222 (54.5) 40/78 (51.3) .623
BMI [kg/m2] 26.4  5.8 26.3  5.6 26.8  6.4 .537
Current smoker 29/280 (10.4) 19/212 (9.0) 10/68 (14.7) .176
Prior cardiovascular intervention 107/300 (35.7) 76/222 (34.2) 31/78 (39.7) .382
Prior BAV 13/300 (4.3) 6/222 (2.7) 7/78 (9.0) .019
Comorbidities
CAD 183/300 (61.0) 137/222 (61.7) 46/78 (59.0) .670
Hypertension* 230/298 (76.7) 174/220 (79.1) 56/78 (71.8) .187
Diabetesy 79/298 (26.5) 55/220 (25.0) 24/78 (30.8) .321
Prior stroke/TIA 43/300 (14.3) 29/220 (13.1) 14/78 (18.0) .289
PAD 127/300 (42.3) 106/222 (47.8) 21/78 (26.9) .001
Cancer 59/300 (19.7) 42/222 (18.9) 17/78 (21.8) .583
Pulmonary diseasez 78/300 (26.0) 60/222 (27.0) 18/78 (23.1) .494
Pulmonary hypertensionx 95/296 (32.1) 68/218 (31.2) 27/78 (34.6) .578
Renal insufficiencyk 94/300 (31.3) 65/222 (29.3) 29/78 (37.2) .196
Prior MI 46/298 (15.4) 33/221 (14.9) 13/77 (16.9) .683
Symptoms
Dizziness with exertion 105/300 (35.0) 78/222 (35.1) 27/78 (34.6) .934
CCS angina class III/IV 40/280 (14.3) 33/212 (15.6) 7/68 (10.3) .280
ECG
AV block 39/291 (13.4) 29/215 (13.5) 5/76 (6.6) .324
LBBB 43/296 (14.5) 33/220 (15.0) 10/76 (13.2) .593
RBBB 33/287 (11.5) 23/211 (10.9) 10/76 (13.2) .844
Echocardiogram
LVEF [%] 52.5  12.3 52.7  11.7 52.0  14.0 .657
Peak transvalvular gradient [mm Hg] 71.5  23.3 71.0  22.9 73.1  24.5 .581
Mean transvalvular gradient [mm Hg] 44.3  15.3 44.3  15.1 44.3  16.1 .987
Moderate/severe regurgitation insufficiency 42/300 (14.0) 24/222 (10.8) 18/78 (23.1) .007
NYHA class III/IV 226/298 (75.8) 179/220 (81.4) 47/78 (60.3) .001
STS [%] 9.0  7.6 9.3  7.7 8.3  7.2 .330
SD, Standard deviation; TAo-TAVI, transaortic transcatheter aortic valve implantation; BMI, body mass index; BAV, balloon aortic valvuloplasty; CAD, coronary artery disease;
TIA, transient ischemic attack; PAD, peripheral artery disease;MI, myocardial infarction; CCS, Canadian Cardiovascular Society; ECG, electrocardiogram; AV, atrioventricular;
LBBB, left bundle branch block; RBBB, right bundle branch block; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; STS, Society of Thoracic Sur-
geons. *Defined as systolic blood pressure greater than 140 mm Hg, diastolic blood pressure greater than 90 mm Hg, or a documented history of hypertension. yDefined as docu-
mented history of diabetes. zDefined as any condition causing or indicating impaired lung function. xDefined as mean pulmonary artery pressure greater than 25mmHg. kDefined
as creatinine level greater than 3.0 mg/dL.





The most commonly used THV size was 26 mm
(48.3% overall) (Table 2). Device success was achieved
in 98.7% of all patients. Procedural duration, volume
of contrast agent used, and requirement for balloon post-
dilation were not significantly different between conven-
tional and direct TAo-TAVI groups. Likewise, the median
length of stay in the intensive care unit and time to
discharge were comparable. There was no case of an
inability to cross the aortic valve in the direct group,
whereas this was a problem for 2 patients in the conven-
tional group.918 The Journal of Thoracic and Cardiovascular SurgA borderline significant trend toward fewer procedural
complications in the direct TAo-TAVI group compared
with the conventional group was apparent (3.9% vs
11.3%; P ¼ .053). The most common of these was com-
plete atrioventricular (AV) block (5.0% overall), with no
statistical difference between groups. However, 2 cases of
AV block occurred during the BAV predilation step in the
conventional group. A significantly higher proportion of
conventional TAo-TAVI patients required PPI (5.0%;
84.6% of AV block cases) compared with patients in the
direct group (0.0%; P ¼ .034). The frequencies of access
complications and conversion to open surgery were notery c March 2018
TABLE 2. Periprocedural and hospitalization details
Total (N ¼ 300)
mean ± SD/n/N (%)
Conventional
TAo-TAVI (N ¼ 222)
mean ± SD/n/N (%)
Direct TAo-TAVI
(N ¼ 78)





Distance to annulus from puncture site [cm] 6.3  1.4 6.2  1.1 6.8  2.1 .074
Access point .086
Ministernotomy 288/300 (96.0) 216/222 (97.3) 72/78 (92.3)
Right anterior thoracotomy 12/300 (4.0) 6/222 (2.7) 6/78 (7.7)
Predilation balloon size [mm] 20.9  1.9 20.9  1.9 NA NA
THV size .728
23 mm 83/300 (27.7) 59/222 (26.6) 24/78 (30.8)
26 mm 145/300 (48.3) 110/222 (49.6) 35/78 (44.9)
29 mm 72/300 (24.0) 53/222 (23.9) 19/78 (24.4)
Procedural duration [min] 107.0  37.7 105.6  37.3 110.9  38.6 .279
Contrast agent volume [mL] 101.4  48.6 104.1  43.8 94.7  58.7 .157
Balloon postdilation 70/300 (23.3) 50/222 (22.5) 20/78 (25.6) .575
Periprocedural complications 28/300 (9.3) 25/222 (11.3) 3/78 (3.9) .053
Access complications* 6/300 (2.0) 6/222 (2.7) 0/78 (0.0) .345
Device malfunctiony 2/300 (0.7) 2/222 (0.9) 0/78 (0.0) .400
Second valve 5/300 (1.7) 4/222 (1.8) 1/78 (1.3) .758
Conversion to open surgery 5/300 (1.7) 5/222 (2.3) 0/78 (0.0) .393
Complete AV block 15/300 (5.0) 13/222 (5.9) 2/78 (2.6) .251
During BAV predilation 2/15 (13.3) 2/13 (15.4) NA NA
During valve implantation 6/15 (40.0) 6/13 (46.2) 0/2 (0.0) .215
Complete AV block requiring PPI 11/300 (3.7) 11/222 (5.0) 0/78 (0.0) .034
Procedural outcomes
Device successz 296/300 (98.7) 219/222 (98.6) 77/78 (98.7) >.999
Periprocedural mortality 0/300 (0.0) 0/222 (0.0) 0/78 (0.0) NA
Moderate/severe paravalvular regurgitation 10/ 300 (3.3) 9/222 (4.1) 1/78 (1.3) .463
Peak transvalvular gradient [mm Hg] 17.6  7.8 17.9  7.9 16.5  6.9 .328
Mean transvalvular gradient [mm Hg] 9.8  4.6 9.8  4.5 9.7  5.0 .857
Hospitalization
Length of stay in ICU [d]x 1.0 (1.0-3.0) 1 (1.0-2.0) 2.0 (1.0-3.0) .052
Time to discharge post-TAVI [d]k 8 (6.0-11.0) 7 (5.8-10.0) 8 (7.0-14.0) .005
SD, Standard deviation; TAo-TAVI, transaortic transcatheter aortic valve implantation; NA, not applicable; THV, transcatheter heart valve; AV, atrioventricular; BAV, balloon aortic
valvuloplasty; PPI, permanent pacemaker implantation; ICU, intensive care unit; TAVI, transcatheter aortic valve implantation. *Defined as annular/aortic dissection/rupture or
uncontrolled bleeding. yDefined as failure to meet any device performance specifications or perform as intended. zDefined as absence of procedural mortality, correct positioning,
and intended performance of THV (VARC-2 criteria (11)). xData for 9 patients missing (conventional 4, direct 5). kData for 3 patients missing (conventional 0, direct 3).






statistically different between groups, and no periproce-
dural death occurred in either group.
Procedural Efficacy
Immediately after TAo-TAVI, overall peak and mean
transvalvular gradients were reduced to 17.6 and 9.8 mm
Hg, respectively, with no notable differences between con-
ventional and direct groups (P¼ .328 and P¼ .857, respec-
tively) (Table 2). The majority of patients in both groups
displayed no/trace PVL after TAVI (82.1% and 76.6% of
the direct and conventional groups, respectively; P ¼ .328)
(Figure 2). Likewise, no significant differences were found
for any other procedural outcomes.
Thirty-Day Outcomes
At 30 days postprocedure, 293 patients (97.7%) were
available for follow-up: 219 (98.6%) in the conventionalThe Journal of Thoracic and Cagroup and 74 (94.9%) in the direct group (Table 3). Missing
patients were excluded from analyses.
The VARC-2 early safety composite end point was met by
comparable proportions of patients in the conventional and
direct groups (17.4% and 22.7%, respectively; P ¼ .308),
with 18.7% and 20.5% meeting the clinical efficacy com-
posite end point, respectively (P ¼ .731). After adjusting
for baseline characteristics, multivariate analysis indicated
that the omission of BAV predilation had no significant effect
on the odds of meeting either composite end point at 30 days
(early safety: OR, 1.17; 97.5% CI, 0.53-2.62 and clinical ef-
ficacy: OR, 1.14; 95% CI, 0.51-2.55).
Because there were too few outcomes for the model to
function for the individual events or complications over
the first 30 days after the TAo-TAVI procedure, we omitted
calculating the OR and displayed the descriptive rates
only.rdiovascular Surgery c Volume 155, Number 3 919
FIGURE 2. Severity of PVL after conventional versus direct TAo-TAVI. TAo-TAVI, Transaortic transcatheter aortic valve implantation; PVL, paravalvular
leak.





Overall, omission of the BAV predilation step during
TAo-TAVI with the balloon-expandable Edwards SAPIEN
XT or 3 THV was found to have no significant effect on
safety and efficacy outcomes at 30 days, including
VARC-2 composite end points. However, the direct
approach did appear to reduce the frequency of periproce-
dural AV block requiring PPI.Patient Characteristics
The overall low frequency of PAD in the present patients
is surprising, given that this is a common reason for per-
forming TAo-TAVI over TF-TAVI.12 However, a recent
observational study was in agreement with our finding, re-
porting only 32% of TAo-TAVI cases to have PAD.13 Other
reasons to perform TAVI via the TAo route include femoral
artery tortuosity, small access vessel diameter, and surgeon
preference, the latter of which is a particular influence in
real-world registries.
Few of the baseline characteristics of the 2 groups varied
to any great extent. This was with the exception of the pres-
ence of PAD, moderate/severe regurgitation insufficiency,
and NYHA class, all of which were poorer in the patients
who underwent BAV predilation. This indicates that the
condition of the native valve was worse in these patients,
which may have contributed to the physician’s decision to
perform BAV. Unfortunately, neither the reason for the920 The Journal of Thoracic and Cardiovascular Surgphysician’s choice of conventional or direct TAo-TAVI
nor the prevalence of aortic root calcification was recorded
in the ROUTE registry; therefore, this cannot be confirmed.
However, the degree of valve calcification is known to be
less restrictive in TAo-TAVI compared with TF-TAVI
because of the shorter access route and increased control.
Thus, a proportion of BAV decisions were likely to be based
simply on surgeon preference. Finally, a higher proportion
of the direct group had previously received BAV, which
may be another possible reason for them not requiring it
before the TAVI procedure.
Periprocedural Data
An extremely high rate of device success was achieved in
both direct and conventional TAo-TAVI groups. First, this
suggests that the decision not to perform BAV predilation
was appropriate for the patients in the direct group, with
only 1 patient not achieving device success, which was
due to a finding of moderate/severe PVL. Recent studies as-
sessing the effects of omitting predilation from TF- and TA-
TAVI procedures have demonstrated the safety and efficacy
of this approach.3,14-16 Therefore, it is likely that there was a
proportion of the conventional group that would have
achieved device success in the absence of BAV; however,
because of the nonrandomized design of the study, we
were unable to confirm this.
The finding that patients undergoing conventional and
direct TAo-TAVI had a similar procedural duration andery c March 2018
TABLE 3. Multivariable analyses showing the effect of omitting balloon aortic valvuloplasty predilation on 30-day outcomes
Total (N ¼ 293)
n (%)
Conventional







30-d follow-up 293/300 (97.7) 219/222 (98.6) 74/78 (94.9) NA
Composite end points
Early safetyy 55/294 (18.7) 38/219 (17.4) 17/75 (22.7) 1.17 (0.53-2.62)
Clinical efficacyz 56/292 (19.2) 41/219 (18.7) 15/73 (20.5) 1.14 (0.51-2.55)
All-cause mortality 18/293 (6.1) 12/219 (5.5) 6/74 (8.1)
Nonfatal stroke/TIA 4/293 (1.4) 3/219 (1.4) 1/74 (1.4)
Nonfatal MI 2/293 (0.7) 1/219 (0.5) 1/74 (1.4)
Life-threatening bleeding 10/293 (3.4) 8/219 (3.7) 2/74 (2.7)
AKI (AKIN stage 2 or 3) 27/285 (9.5) 19/214 (8.9) 8/71 (11.3)
Major vascular complication 10/293 (3.4) 8/219 (3.7) 2/74 (2.7)
PPIx 26/294 (8.8) 20/220 (9.1) 6/74 (8.1)
Valve-related dysfunction 3/282 (1.1) 3/213 (1.4) 0/69 (0)
Valve-related symptoms requiring hospitalization 10/282 (3.5) 7/213 (3.3) 3/69 (4.3)
NYHA class III/IV 34/282 (12.1) 27/213 (12.7) 7/69 (10.1)
CCS angina class III/IV 7/241 (2.9) 4/196 (2.0) 3/45 (6.7)
TAo-TAVI, Transaortic transcatheter aortic valve implantation; OR, odds ratio; CI, confidence interval; NA, not applicable; TIA, transient ischemic attack; MI, myocardial
infarction; AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; PPI, permanent pacemaker implantation; NYHA, New York Heart Association; CCS, Canadian Car-
diovascular Society. *Adjusted for baseline characteristics, age, presence of PAD, moderate/severe regurgitation insufficiency, prior BAV, and NYHA class III or IV. yComposite
of all-cause mortality, nonfatal stroke/TIA, life-threatening bleeding, acute kidney injury, major vascular complication, and valve-related dysfunction. zComposite of all-cause
mortality, stroke, hospitalization for valve-related symptoms, NYHA class III or IV, and valve-related dysfunction. xPatients with PPI before being lost to follow-up are included.






volume of contrast agent is unsurprising, given that the short
distance between the access site and the aortic annulusmeans
that BAV represents only a small proportion of the overall
operative time. A similar result has been reported for direct
versus conventional TA-TAVI,17 which also involves a short
access route. Conversely, direct TF-TAVI has been consis-
tently noted to save time by avoiding lengthy negotiation
of the femoral artery with the BAV equipment.3,4,6,7,16
It may be expected that, in the absence of BAV predila-
tion, there would be a greater need for postprocedural dila-
tion in the direct TAVI group. However, no significant
difference in the rate of balloon postdilation was seen be-
tween the 2 groups in the present study. This is consistent
with findings from studies assessing the value of BAV pre-
dilation in TA- and TF-TAVI procedures using balloon-
expandable prostheses3,7,15-17 and implies that satisfactory
expansion of the THV may not be reliant on the
predilation step. This is an important finding, because
postdilation has been identified as an independent
predictor of major adverse cardiac and cerebrovascular
events at 1 year.18 However, it should be noted that the base-
line characteristics of the patients included in the present
analysis indicate that the native valves of those who
received BAV predilation were in a worse condition before
TAVI. Therefore, it is possible that in the absence of BAV,
more of these patients would have required postdilation.The Journal of Thoracic and CaPeriprocedural Complications
Although no difference in periprocedural mortality was
observed between the 2 study groups, there was a trend to-
ward a reduced rate of complications after direct TAo-
TAVI. The borderline significance for this effect may have
been due to the generally low incidence of complications
coupled with relatively small patient numbers. This sug-
gests that omitting BAV predilation may hold promise for
improving procedural safety for many patients, and this
merits investigation in larger studies.
More specifically, a significant difference between
groups was seen in relation to the requirement for PPI after
complete AV block, which applied to 5% of conventional
patients but to none of the direct patients. It is notable
that 2 of 13 instances of complete AV block in the conven-
tional group occurred during the BAV predilation step. A
trend toward reduced PPI with direct TAVI has been re-
ported in a number of studies.6,8 Furthermore, BAV
predilation has been identified as an independent
predictive factor for PPI requirement in TAVI (OR, 1.75;
95% CI, 1.02-3.02; P¼ .04).19 Prior conduction abnormal-
ities also have been associated with a greater requirement
for PPI post-TAVI19; however, neither the prevalence of
AV block nor right or left bundle branch block varied be-
tween the 2 groups at baseline in the present analysis. On
the other hand, the potentially inferior condition of therdiovascular Surgery c Volume 155, Number 3 921




native valves in the conventional group, which was indi-
cated by the baseline characteristics, may have been a
contributing factor. Data regarding aortic root calcification
may help to clarify this hypothesis. In combination with
studies investigating direct TF- or TA-TAVI, our data sug-
gest that eliminating BAV from the procedure may reduce
the periprocedural need for PPI for some patients.
Early Safety/Efficacy
No differences in the rates of patients meeting early
safety/efficacy end points at 30 days, including the
VARC-2 composite measures and each of their elements
considered individually, were seen between groups.11 This
suggests that BAV predilation in TAo-TAVI has little to
no short-term clinical value for many patients. Previous
studies evaluating the role of predilation in TF- and TA-
TAVI also have come to this conclusion,3,7,8,14-18
indicating that this finding appears to be applicable
regardless of access route.
Several TF-TAVI studies have associated the omission of
BAV predilation with reduced stroke rates16,18; however,
this was not the case in the present study, with identical
rates of nonfatal stroke/transient ischemic attack in the 2
groups. This may be explained by the additional stroke
risk posed by the TF access route (due to the abrasion of
lengthy arterial lumens and potential dislodgement of
atherosclerotic material), and therefore the greater
capacity for reducing this risk by omitting the passage of
the BAV device. Such an effect likely would be negligible
with TAo access because of the short distance between
the point of catheter insertion and the aortic valve. In this
case, debris from the valve itself would be the cause of
stroke. It is possible that a higher rate of stroke would be
found in the conventional group compared with the direct
group if a larger population was evaluated, with only 4
patients overall experiencing such an event in the present
study. Future studies should carefully monitor this
important safety outcome.
Study Limitations
First, the assignment of patients in the conventional or
direct groups was dependent on the treatment decision
taken by the intervening physician, rather than randomiza-
tion. Baseline characteristics such as frequency of athero-
sclerotic disease, moderate/severe aortic regurgitation
insufficiency, and NYHA class III/IV, as well as the degree
of aortic root calcification, which was not recorded in the
registry, would likely have influenced the decision of
whether or not to perform BAV. Therefore, there was an
imbalance in the characteristics of the 2 groups that would
have influenced the observed differences in outcomes. To
minimize such effects, 30-day outcomes were adjusted for
PAD, moderate/severe regurgitation insufficiency, and
NYHA class III/IV at baseline. Second, because evaluating922 The Journal of Thoracic and Cardiovascular Surgthe role of BAV predilation was not an original aim of the
ROUTE registry, data relating to justification of its omis-
sion/inclusion were not systematically recorded. Accord-
ingly, not all of the variables accounting for selection
were necessarily captured, and the multicenter nature of
the study means that institutional preferences are likely to
have played a role. Third, statistical power was limited by
the smaller number of patients who received direct TAo-
TAVI, with the low event rates potentially resulting in over-
fitting of the data at multivariable analysis. Because our
intention was merely to describe the observed relationship
between BAV and outcome variables in the present study,
we restricted the multivariable model to clinical safety
and efficacy composite end points. Finally, sole use of a
balloon-expandable SAPIEN THV means that findings are
not necessarily applicable to other valves and deployment
systems, such as self-expandable valves.CONCLUSIONS
The elimination of BAV predilation from TAo-TAVI with
an Edwards SAPIEN balloon-expandable valve appears to
be safe and not to affect the success of the procedure in
the majority of patients. Although there is likely a propor-
tion of patients who received TAVI who will still require
BAV because of the condition of the native valve and aortic
root, it appears to be unnecessary in many cases. This is in
agreement with prior studies concerning TA- and TF-TAVI.
The present real-world data suggest that physicians might
consider using a direct rather than a conventional approach
in TAo-TAVI. However, larger, randomized studies would
be informative to confirm present findings.Conflict of Interest Statement
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